

**SANGAMO THERAPEUTICS, INC.**  
**501 Canal Blvd.**  
**Richmond, California 94804**

November 18, 2024

VIA EDGAR

United States Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549  
Attn: Doris Stacey Gama

**RE: Sangamo Therapeutics, Inc.**  
**Registration Statement on Form S-3**  
**File No. 333-283179**

**Acceleration Request**  
**Requested Date: November 19, 2024**  
**Requested Time: 5:00 p.m. Eastern Time**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Exchange Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-283179) (the "**Registration Statement**") to become effective at 5:00 p.m. Eastern Time on November 19, 2024, or as soon thereafter as is practicable.

Once the Registration Statement has been declared effective, please orally confirm that event with Chadwick Mills at (650) 843-5654 or Courtney Tygesson at (312) 881-6680 of Cooley LLP, counsel to the registrant.

[Signature page follows]

Sincerely,

**SANGAMO THERAPEUTICS, INC.**

By: /s/ Scott B. Willoughby  
Scott B. Willoughby  
Senior Vice President, General Counsel and Corporate Secretary

cc: Alexander D. Macrae, Sangamo Therapeutics, Inc.  
Prathyusha Duraibabu, Sangamo Therapeutics, Inc.  
Chadwick Mills, Cooley LLP  
Courtney Tygesson, Cooley LLP

---